Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
äŒæ¥ã³ãŒãASBP
äŒç€ŸåAspire Biopharma Holdings Inc
äžå Žæ¥Feb 18, 2022
æé«çµå¶è²¬ä»»è
ãCEOã- -
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 18
æ¬ç€Ÿæåšå°194 Candelaro Drive, #233
éœåžHUMACAO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœPuerto Rico
éµäŸ¿çªå·00791
é»è©±çªå·
ãŠã§ããµã€ã
äŒæ¥ã³ãŒãASBP
äžå Žæ¥Feb 18, 2022
æé«çµå¶è²¬ä»»è
ãCEOã- -
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã